Retinal Consultants of Arizona
Quick facts
Marketed products
- Lucentis every 12 weeks · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. - Lucentis every 4 weeks · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. - Lucentis (Treat and extend) · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Retinal Consultants of Arizona portfolio CI brief
- Retinal Consultants of Arizona pipeline updates RSS
Frequently asked questions about Retinal Consultants of Arizona
What are Retinal Consultants of Arizona's marketed drugs?
Top marketed products include Lucentis every 12 weeks, Lucentis every 4 weeks, Lucentis (Treat and extend).
Related
- Lucentis every 12 weeks · Ophthalmology
- Lucentis every 4 weeks · Ophthalmology
- Lucentis (Treat and extend) · Ophthalmology
- Sector hub: All tracked pharma companies